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Calcium-sensing receptorThe “amyloid-β (Aβ) hypothesis” posits that accumulating Aβ peptides (Aβs) produced by neurons cause
Alzheimer's disease (AD). However, the Aβs contribution by the more numerous astrocytes remains
undetermined. Previously we showed that ﬁbrillar (f)Aβ25–35, an Aβ42 proxy, evokes a surplus endogenous
Aβ42 production/accumulation in cortical adult human astrocytes. Here, by using immunocytochemistry,
immunoblotting, enzymatic assays, and highly sensitive sandwich ELISA kits, we investigated the effects of
fAβ25–35 and soluble (s)Aβ25–35 on Aβ42 and Aβ40 accumulation/secretion by human cortical astrocytes and
HCN-1A neurons and, since the calcium-sensing receptor (CaSR) binds Aβs, their modulation by NPS 2143,
a CaSR allosteric antagonist (calcilytic). The fAβ25–35-exposed astrocytes and surviving neurons produced, accu-
mulated, and secreted increased amounts of Aβ42, while Aβ40 also accrued but its secretion was unchanged. Ac-
cordingly, secreted Aβ42/Aβ40 ratio values rose for astrocytes and neurons. While slightly enhancing Aβ40
secretion by fAβ25–35-treated astrocytes, NPS 2143 speciﬁcally suppressed the fAβ25–35-elicited surges of endog-
enous Aβ42 secretion by astrocytes and neurons. Therefore, NPS 2143 addition always kept Aβ42/Aβ40 values to
baseline or lower levels. Mechanistically, NPS 2143 decreased total CaSR protein complement, transiently raised
proteasomal chymotrypsin activity, and blocked excess NO production without affecting the ongoing increases
in BACE1/β-secretase and γ-secretase activity in fAβ25–35-treated astrocytes. Compared to fAβ25–35, sAβ25–35
also stimulated Aβ42 secretion by astrocytes and neurons and NPS 2143 speciﬁcally and wholly suppressed
this effect. Therefore, since NPS 2143 thwarts any Aβ/CaSR-induced surplus secretion of endogenous Aβ42 and
hence further vicious cycles of Aβ self-induction/secretion/spreading, calcilytics might effectively prevent/stop
the progression to full-blown AD.
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Human brain's healthy neurons constitutively make and during
synaptic activity release the amyloid beta peptides (Aβs), which are
cleavage products of the sequential activities of BACE1/β-secretase
(β-S) and γ-S enzymes on the transmembrane Aβ precursor protein
(APP) [1]. Two of the produced Aβ isoforms prevail, i.e. Aβ40 (90%)
and Aβ42 (10%), the ratio of which changes in favor of Aβ42 in
Alzheimer's disease (AD) [2,3]. At its C-terminus Aβ40 lacks two
hydrophobic amino acids, Ala and Ile, which confer to Aβ42 its greater
aggregation, higher resistance to proteolysis, and more intense
cytotoxicity [2,3]. Various mechanisms, which fail in AD, keep the
extracellularly released Aβs at physiological (~pM) levels, including
degradation by various proteases, ingestion by microglia, and trans-
port into the blood via the α2-macroglobulin receptor/low density
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At physiological pM concentrations Aβs preserve neuronal viability,
hippocampal synaptic plasticity, and memory recording ability [5,6].
Since BACE1/β-S is more intensely expressed in neurons than in
glial cells (e.g. astrocytes), brain neurons are deemed to be the main
source of Aβs [1,2,7].
Conversely, pathological increases in brain tissue Aβs levels and the
deposition of Aβ-containing senile plaques in the neuropil together
with neuroﬁbrillary tangles and chronic neuroinﬂammation are the
main hallmarks of AD [2,4,8]. The intra- and extracellular accrual of
Aβs may be due to (i) an Aβs overproduction driven by mutations of
APP or presenilin 1 (PSEN1) or presenilin 2 (PSEN2) genes in the rare
early-onset familial AD (EOFAD) or (ii) an ageing-related failure of
Aβ-clearing mechanisms in the common late-onset AD (LOAD) [2,4,8].
During the slow (~5-to-15 years) progression of AD, accumulating
Aβs target all types of nerve and cerebrovascular cells and elicit com-
plex harmful effects, such as loss of synapses, NFTs, neurotoxicity,
neurodegeneration, cerebrovascular damage, and proinﬂammatory
astrocytes' and microglia's activation, all of which concur with a
progressive loss of the patient's cognitive functions [1,4,9–11].
Aβ-activated microglia phagocytize ﬁbrillar (f) and soluble (s)Aβs,
favor Aβs ﬁbrillation inside dense core senile plaques, and release, be-
sides proinﬂammatory cytokines, nitric oxide (NO) and reactive oxygen
species (ROS) leading to the formation of highly toxic peroxynitrite
(ONOO—\) [2,4,9–11]. But astrocytes' roles in AD development should
not be neglected as they are 5-to-10-foldmore numerous than neurons,
form wide gap-junctionally interconnected networks, are essential
components of tripartite synapses, and tightly “cradle” neurons insulat-
ing them from external “chemical noise” while exchanging with them
various physiologically essential compounds (reviewed in [12–14]).
Such a physical and functional intimacy means that astrocytes may
also be vulnerable to a direct attack by neuron-released and/or extracel-
lularly accumulating Aβ oligomers and ﬁbrils. So how might the astro-
cytes respond to these? According to one view, astrocytes are cellular
janitors that sweep up the Aβs, which they take up via LRP1, LRP2/
Megalin, and other receptors, accumulate, enzymatically degrade, and
in dying release favouring the formation of smaller, GFAP-rich, cortical
Aβ senile plaques [15]. Although initially beneﬁcial, the astrocytes'
engagement in clearing excess amounts of Aβs ends up competing
with and hence impairing their neuron-supporting functions [12–17].
Moreover, Aβ25–35-activated murine astrocytes produce and secrete
apoptogenic prostate apoptosis response-4 (PAR-4) protein and
ceramide-loaded exosomes (“apoxosomes”) perhaps to kill, and thus
protect themselves from, excess Aβs-releasing neurons [18]. Notwith-
standing their huge numbers, the contribution of astrocytes' own Aβs
production to the development of AD has received comparatively little
consideration; but, were astrocytes' Aβs production even modestly
intensiﬁed, it would hugely increase brain's Aβs load [19]. Blasko et al.
[20] reported that human astrocytes produce Aβ40 and Aβ42 when
stimulated by interferon (IFN)-γ + tumor necrosis factor (TNF)-α or
interleukin (IL)-1β, all cytokines released from the Aβ-activated mi-
croglia within senile plaques [9–11]. Recently, Zhao et al. [21] reported
that a TNF-α + IFN-γmixture or sAβ42 or fAβ42 increased endogenous
BACE1 and APP levels, and Aβ40 secretion by activated primary astro-
cytes isolated from the cerebral cortex of neonatal mouse pups; they
suggested that a feed-forward mechanisms would drive Aβ production
in rodent astrocytes under neuroinﬂammatory conditions. And we
showed that adding fAβ25–35, a proxy retaining the main physical and
biological features of Aβ42 [22], stimulated untransformed adult
human astrocytes isolated from fragments of the temporal lobe cerebral
cortex to synthesize and accumulate large amounts of endogenous Aβ42
and its oligomers [23]. Themolecularmechanism(s) underlying this ex-
ogenous Aβ⇒ endogenous Aβ induction in astrocytes remained to be
elucidated: the interaction of exogenous Aβs with some component(s)
located at the outer surface of the cells' plasmamembrane seemed to be
likely. It was also to be established whether this Aβ self-inducingfeed-forward mechanism might operate in human neurons too, al-
though this was reported to occur in cultures of dissociated rat cortical
neurons and mouse hippocampal slices [24].
Several reports indicate that both sAβ oligomers and fAβ aggre-
gates bind/activate a number of cell membrane receptors, like p75
neurotrophin receptor (p75NTR) [25], Frizzled receptor [26], insulin
receptor [27], N-methyl D-aspartate (NMDA) glutamate receptor
[28], α7 nicotinic acetylcholine receptor (α7nAChR) [29], apolipopro-
tein E (APOE) receptors [30] scavenger receptor for advanced
glycation endproducts (RAGE) [31], formyl peptide receptor-like 1
(FPRL1/2) [32], cellular prion protein (PrPc) acting as an Aβ oligomer
receptor [33], and the calcium-sensing receptor (CaSR) [34]. As none
of such receptors exclusively binds Aβs, the existence and/or speciﬁc-
ity of several of these Aβ/receptor interactions has been the object of
controversy. But in some cases, the internalization of Aβ/receptor
complexes resulted in intracellular accumulation of Aβs (reviewed
in [35]). In other instances, speciﬁc Aβ/receptor complexes were
formed, but could not be rapidly internalized due to the ﬁbrils' mechan-
ical hindrance: yet, the resulting persistent aberrant signalling from the
Aβ-bound receptors profoundly altered neurons' critical functions with
toxic and/or deadly outcomes, as for instance in SK-N-BE neuroblasto-
ma cells engineered to over-express the whole p75NTR molecule [25].
In previous work, we showed that NPS 89686, a CaSR allosteric antago-
nist (calcilytic) [36], suppressed the MEK/ERK-mediated nitric oxide
(NO) overproduction in adult human astrocytes exposed to a mixture
of three cytokines (IFN-γ, TNF-α, and IL-1β) or to sAβ40 [37,38] or
fAβ25–35 or fAβ1–42 (unpublished; see the Results section) thereby
indicating the occurrence of a speciﬁc Aβ/CaSR interaction. Therefore,
we undertook to further investigate the roles of the CaSR in AD
development.
The CaSR belongs to family C of G-protein-coupled receptors (GPCRs)
(reviewed in [39]). Structurally, the CaSR's huge (~612 amino acids) ex-
tracellular N-terminal, the Venus Flytrap (VFT) domain, is joined via a
cysteine-rich region to seven transmembrane α-helices (TM1–TM7)
joined by extra- and intracellular loops (the 7TM region), while two do-
mains of the intracellular C-terminal tail are crucial for CaSR's expression
at the cell surface and its complex signalling activities [39]. Once inserted
in the plasma membrane, the CaSR forms homodimers (CaSR/CaSR) or
heterodimers (CaSR/mGluR1α) via disulﬁde-bonds andnon-covalent in-
teractions, even though it may function as a monomer [40]. CaSR dimer-
ization also occurs at the endoplasmic reticulum (ER) being needed for
its insertion into the plasma membrane [41]. The two huge VFT lobes
of each CaSR homodimer bind orthosteric (type I) agonists like Ca2+
(the physiological ligand), several other divalent and trivalent cations,
positively charged aminoglycoside antibiotics, and polyamines [39,42].
Extracellular Na+ concentration and aromatic L-α-amino acids are allo-
steric (type II) CaSR agonists and bind various 7TM sites [43]. CaSR
promptly detects and responds to changes in extracellular calcium con-
centration ([Ca2+]e) [44]. The binding of any orthosteric type I agonist
turns the CaSR signalling onvia a rearrangement the 7TMregion, thereby
letting the C-tails interact with various species of G proteins and activate
a variety of intracellular signalling pathways involving second
messenger-producing enzymes (e.g. adenylyl cyclase), lipid kinases
(e.g. phospholipase C, D, A2), protein kinases (e.g. PKCs, MAPKs, AKT),
Ca2+ inﬂuxes through TRPC6-encoded receptor-operated channels,
and transcription factors (reviewed in [39,44]). Like other GPCRs, the
CaSR exhibits the “ligand-biased signalling” feature, i.e. according to the li-
gand involved a speciﬁc CaSR signalling pathway may be preferred over
the others [45]. Modulation of the CaSR's signalling has been related to
gene expression control, MAPK (MEK/ERK and JNK) activations,
cell proliferation, and apoptosis [44–46]. Most important, various
phenylalkylamines endowed with aromatic rings and NH3+ groups
have been synthesized and shown to act either as allosteric agonists
(calcimimetics, e.g. NPS R-568) or antagonistis (calcilytics, e.g. NPS
89636, NPS 2143, etc.) as they are able to shift to the right or left, respec-
tively, the CaSR's response curve to [Ca2+]e changes (see for references
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7TM region, have attracted great interest for their therapeutic potential
in human ailments caused by CaSR mutations or malfunctioning, e.g.
calcimimetics in various forms of hyperparathyroidism and calcilytics
(possibly) in osteoporosis [47,48]. CaSR allosteric modulators may also
induce a “ligand-biased signalling”: in some models calcimimetics NPS
R-568 and calcilytic NPS 2143 were reported to elicit a preference for
intracellular calcium mobilization rather than MEK/ERK1/2 phosphory-
lation [45].
Notably, the CaSR is expressed all over in the brain, in which plays
important physiological roles [49]. A role for the CaSR in AD pathogen-
esis was suggested ﬁrst by the Aβ-induced degeneration of hippocam-
pal neurons apparently linked to surges in cytosolic [Ca2+]i [50], and
then by the fAβ25–35- and fAβ1–40-elicited activation of Ca2+-permeable
non-selective cation channels increasing the [Ca2+]i in the hippocampal
neurons of wild type (WT) CaSR+/+ rats but not of CaSR−/− rats. It
should be recalled in this regard that, like polyamines, Aβs are endowed
with orderly spaced arrays of positive charges [33]. Given the CaSR
ubiquitous brain expression [49], not only hippocampal neurons but
all types of human nervous cells and even cerebrovascular cells might
be vulnerable to any cytotoxic effect elicited via a pathological Aβ/
CaSR signalling. Hence, in this work we have investigated whether the
exogenous Aβ-driven overproduction and accrual of endogenous Aβ42
previously observed in human cortical astrocytes [23] might also
occur in cultured human cortical HCN-1A neurons [51]; and whether
exogenous f- or sAβs might also elicit an excess secretion of Aβ42 and/
or Aβ40 on the part of either neurons or astrocytes or both. Concur-
rently, we have tested the hypothesis that, besides preventing NO
overproduction induced by a mixture of three proinﬂammatory
cytokines (IFN-γ, TNF-α, and IL-1β) [37] or fAβ25–35 or fAβ1–42 (see
the Results section), a CaSR allosteric antagonist (in this instance,
NPS 2143 [48]), might beneﬁcially break the vicious cycle of exoge-
nous Aβs inducing the production, accrual, and maybe secretion of
endogenous Aβs by human cortical astrocytes and/or HCN-1A
neurons. The ﬁndings herein reported reveal that the Aβ/CasR
interaction elicits an excess secretion of Aβ42 by both human
astrocytes and HCN-1A neurons, and that CaSR antagonist NPS
2143 speciﬁcally suppresses the surplus release of endogenous
Aβ42 by the Aβ25–35-exposed human astrocytes and HCN-1A neurons.
Therefore, our ﬁndings denote for the ﬁrst time a possible therapeutic
beneﬁt of this calcilytic agent in preventing vicious cycles of Aβs
self-induction, over-secretion, and spreading, thereby halting the pro-
gression towards full-blown AD.
2. Materials and methods
2.1. Cell cultures
Untransformed human adult astrocytes were isolated from normal
temporal cerebral cortex, cultured, and propagated as previously
described [23]. Brieﬂy, small fragments of temporal lobe cortices
from ﬁve patients who had undergone perforating head injuries due
to motorcycle accidents were dipped into MCDB 153 medium
(Sigma-Aldrich, Milan, Italy), put into a Dewar ﬂask at 4 °C and carried
to the tissue culture laboratory. There they were further cut into tiny
pieces, the cells in which were released by a mild treatment with
0.25% (w/v) trypsin (Eurobio, Les Ulis Cedex, France) in Hank's Basal
Salt Solution (BSS; Eurobio) at 18 °C and triturated with a series of
Pasteur pipettes of decreasing bores. The isolated cells were planted in
culture ﬂasks (BD Biosciences, Le Pont de Claix, France) containing a
medium consisting of 89% (v/v) of a 1:1 mixture of DMEM/F-12
medium (AppliChem GmbH, Darmstadt, Germany), 10% (v/v)
heat-inactivated (at 56 °C for 30 min) foetal bovine serum (FBS;
BioWhittaker Europe, Belgium) and 1% (v/v) of a penicillin–streptomycin
solution (Eurobio) and ﬁbroblast growth factor-2 (FGF-2; 10 ng ml−1,
Sigma). This complete medium was replaced every 2–3 days. When theprimary cultures reached 70% conﬂuence (1–4 weeks), the cellswere de-
tached with 0.25% (w/v) trypsin and 0.02% (w/v) EDTA (Eurobio) in
Hank's BSS, split 1:4 and planted in new ﬂasks. After the third subculture
a homogeneous population of astrocytes obtained and FGF-2 addition
was no longer needed. In these pure cultures, the cells only expressed
astrocyte-speciﬁc markers such as glial ﬁbrillary acid protein (GFAP)
and glutamine synthase (GS). None of the cells expressed neuronal
(enolase), oligodendrocytes (galactocerebroside), microglia (CD-68), or
endothelial cells (factor VIII) markers. These astrocytes proliferated
slowly in serum-enriched DMEM (AppliChem) medium and were by
now phenotypically “locked-in”. But the serum remained essential as its
withdrawal triggered astrocytes' apoptosis. The proliferatively quiescent
astrocyte in conﬂuent cultures started cycling again when subcultured.
At least 15–18 subcultures could be obtained over 2.5 years from a
piece of normal cerebral cortex.
Human cortical nontumorigenic clonal strain, HCN-1A cell line
(Catalog No. CRL-10442), originally derived from postnatal cortical
tissue removed from a patient undergoing hemispherectomy for unilat-
eralmegalencephalywith intractable seizures [51], was obtained frozen
fromATCC Cultures and Products via its partnershipwith LGC Standards
S.r.l. (Sesto San Giovanni, Italy). Rapidly thawed 5 × 105 HCN-1A
neurons (passage 14) were grown on 9 × 22-mm glass cover slips or
30-mm Petri dishes in 2–4 ml ATCC-formulated Dulbecco's modiﬁed
Eagle's medium (DMEM) fortiﬁed with 10% FBS, 4.5 g L−1 glucose,
2.2 g L−1 NaHCO3, and a pH of 7.35. This complete medium was
half-replaced on alternate days. At 70% conﬂuence (1–4 weeks after
seeding), the cells were detached with 0.25% (w/v) trypsin and 0.02%
(w/v) EDTA (Eurobio) in Hank's BSS, split 1:3 or 1:2 and planted in
cover slips or dishes. The already sluggish growth rate of HCN-1A cells
(ﬁve-to-ten days for each cell duplication) tended to decelerate
further at each subculture. Cell proliferation stopped at 80–90% con-
ﬂuence when ~50% of the neurons had grown multiple cytoplasmic
processes of various lengths. HCN-1A neurons do not express GFAP,
but express markers like neuron-speciﬁc enolase, neuroﬁlament
protein, and neurotransmitters like somatostatin (SST), GABA,
glutamate, cholecystokinin-8 (CCK-8), and vasointestinal peptide
(VIP) [51]. The experimental treatments and processing of HCN-1A
neurons were alike those described for the astrocytes.
2.2. Cell numbers
Astrocytes' and HCN-1A neurons' numerical densities in the treated
and untreated culture specimens were assessed under a phase contrast
IM35™ inverted microscope (Zeiss, Germany) by counting, at 500×
magniﬁcation, all of the nuclei present in 12 randomly chosen ﬁelds
(each 29.400 μm2 in area) per single dish. For each determination at
least three separates per culture and four different cultures were exam-
ined. To avoid bias, the specimens were coded and counted by two re-
searchers who were unaware of the key code, and the two results
thus obtained for each sample group were pooled [52].
2.3. Aβ peptides
Aβ25–35 and Aβ1–42 (Bachem) were dissolved at 1.5 mM in PBS.
Fibrillogenesis by Aβ25–35 and Aβ1–42 was (fast minutes) at room tem-
perature and was checked via thioﬂavin-T tests before the experiments
([23] and unpublished data). Non ﬁbrillar sAβ25–35 was dissolved in
DMSO at 4.0 mM (stock solution). The reversemer peptide Aβ35–25
(Bachem) was dissolved in the same way as Aβ25–35, but did not form
ﬁbrils.
2.4. Experimental protocol
Since normally astrocytes and neurons do not proliferate in the
adult human brain, we employed them once they had reachedmitotic
quiescence. At experimental “0 h”, some of such cultures served as
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fAβ1–42 or reversemer Aβ35–25 added to their medium. The dose we
used for the fAβs had been found to be optimal in previous studies
[23,25,53]. sAβ25–35 was given daily in 2 μM doses dissolved in fresh
medium. It must be stressed here that Aβ25–35, an Aβ42 proxy, was
used to speciﬁcally assess the production and secretion of the
endogenous Aβ42 and Aβ40 peptides by the astrocytes and HCN-1A
neurons (see also the Discussion section).
The CaSR allosteric antagonist (calcilytic) NPS 2143 hydrochloride
(2-chloro-6-[(2R)-3-1,1-dimethyl-2-(2-naphtyl)ethylamino-2-hydroxy-
propoxy]-benzonitrile hydrochloride; Tocris Bioscience, UK) [37,47,48]
was dissolved in DMSO and next diluted in the growth medium
at a ﬁnal concentration of 100 nM. The CaSR allosteric agonist
(calcimimetic) NPS R-568 ([(R)-N-(3-methoxy-(ÿ-phenylethyl)-3-
(2-chlorophenyl)-1-propylamine hydrochloride], Tocris) [47] was
also dissolved in DMSO and used at a ﬁnal concentration of 1.0 μM.
Starting at experimental “0 h” time and every 24 h thereafter astrocytes
and HCN-1A neurons were ﬁrst exposed for 30 min to either NPS 2143
or NPS R-568 dissolved in fresh medium; thereafter, fresh (at 0.5 h) or
the previously cell-conditioned (at 24.5 and 48.5 h) media were
added again to the cultures. In one set of experiments, MEK1/MEK2 in-
hibitor U0126 (10 μM; Tocris) was added for 30 min and next washed
out just before fAβ25−35 addition to be administered again at 24 h and
washed out at 24.5 h. Cultures and cell-conditionedmediawere sampled
at 24 hourly intervals. Phosphoramidon (10 μM; Sigma), an inhibitor of
thermolysin and other proteases, was added to themedia at “0 h” exper-
imental time.
2.5. Western immunoblotting (WB)
At selected time points, control and treated adult human astrocytes
were scraped into cold PBS, sedimented at 200 ×g for 10 min, and ho-
mogenized in T–PER™ tissue protein extraction reagent (Pierce-Celbio,
Milan, Italy) containing a complete EDTA-free protease inhibitor
cocktail (Roche, Milan). The protein contents of the samples were
assayed according to Bradford using BSA as standard. Equal amounts
(10–30 μg) of protein from the samples were heat-denatured for
10 min at 70 °C in an appropriate volume of 1× NuPAGE LDS Sample
Buffer supplemented with 1× NuPAGE Reducing Agent (Invitrogen,
Milan). The samples were next loaded on NuPAGE Novex 4–12% Bis–
Tris polyacrylamide gel (Invitrogen) (for CaSR and Aβ42 detection).
After electrophoresis in NuPAGE MES SDS Running Buffers using the
Xcell SureLock™Mini*Cell (Invitrogen) (50-min runtime at 200 V con-
stant), proteins were blotted onto nitrocellulose membranes (0.2 μm;
Pall Life Sciences, Milan). To ensure efﬁcient and reproducible binding
to the membrane, transfer proceeded under low power conditions
(30 V constant) for 1 h in 1× NuPAGE transfer buffer containing 10%
methanol. Immunoblotswere performedusing the SNAP i.d. protein de-
tection system (Merck-Millipore, Milan). The membranes were probed
with: (i) the speciﬁc mouse monoclonal 12F4 antibody against Aβ42
raised using as immunogen a peptide corresponding to the C-terminal
amino acids 37–42 of Aβ42 coupled to Keyhole limpet hemocyanin
(KLH), an in vivo immunostimulant, through the addition of an
N-terminal cysteine (Merck-Millipore); before use it was diluted 1:300
according to the seller's documentation; 12F4 antibody cross-reacts
with neither Aβ1–43 nor Aβ1–40 nor Aβ25–35 [23]; (ii) the speciﬁc mouse
monoclonal HL1499 antibody against the CaSR (Sigma), raised using as
an in vivo immunogen a peptide corresponding to amino-acids 15–29
of the CaSR extracellular N-terminus; it was used at a ﬁnal 3.0 μg ml−1
as previously detailed [23]; (iii) mouse monoclonal 5C3 anti-Aβ40 anti-
body (Acris, Germany), raised using as an immunogen a C-terminal
peptide conjugated with KLH, does not cross-react with either Aβ42 or
Aβ25–35 aswe ourselves conﬁrmed via gel electrophoresis and immuno-
blotting (not shown); 5C3 antibody was used at 1.0 μg ml−1; (iv) an
antibody against lamin B1 (C-20, Santa Cruz Biotechnology, Germany)
was used at 1.0 μg ml−1 to assess the loading controls. The integratedintensities of the bands speciﬁc for each protein of interest were
assessed using the Sigmagel™ software package (Jandel Corp., Erkrath,
Germany).
2.6. Fluorescence microscopy
Control and treated HCN-1A neurons were ﬁxed for 20 min with
4% paraformaldehyde (PAF) at room temperature. Next, cells were
washed with Tris buffered saline (TBS—0.05 M L−1 Tris base, 9 g/L
NaCl, pH 8.4), four times for 5-min each time, and then perme-
abilized with 0.05% Triton X-100 in TBS. To saturate unspeciﬁc
binding sites, cells were incubated for 1 h at room temperature
with a blocking solution containing 2.0% FBS, 2.0% BSA, and 0.02%
Triton X-100 in TBS (TBS-TX). Immunoﬂuorescence staining for
Aβ42 and Aβ40 was done with the respective mouse monoclonals:
anti-Aβ42 (8G7, 1.0 μg ml−1; Acris), and anti-Aβ40 (5C3;
5.0 μg ml−1; Acris). After three washes with TBS-TX (four changes
in 10 min), the cells were incubated with the secondary antibody,
chicken anti-mouse Alexa Fluor 488 used at 1.0 μg ml−1 (Molecular
Probes, Invitrogen). This was followed by 10 min incubation with
1.0 ng ml−1 of 4′,6′-diamidino-2-phenylindole dihydrochloride
(DAPI; Sigma-Aldrich) to stain DNA. Coverslips were mounted in
anti-bleaching medium (Dabco, Sigma-Aldrich). The negative con-
trol procedure omitted the primary antibody. Confocal microscopy
analysis was performed on a Leica TCS SP5 AOBS confocal micro-
scope (Leica-Microsystems) equipped with violet (405 nm laser),
blue (Argon, 488 nm), orange (543 nm), and red (633 nm, HeNe
laser) excitation laser line. A 63×/1.40 NA oil-immersion objective
(PL APO 63×, Leica-Microsystem, Germany) was employed for the
specimens' analysis.
2.7. Assays of secretases (S) activities
Untreated and treated adult human astrocytes were harvested
with a cell scraper, pelleted, and washed once in ice-cold PBS. They
were next re-suspended in 20 mM Hepes, pH 7.5, 50 mM KCl,
2.0 mM EGTA, and a complete protease inhibitor mixture (Roche),
and homogenized using a Dounce homogenizer. Cell lysates were
centrifuged at 800 ×g for 10 min to remove nuclei and cell debris
and the resulting supernatant was stored at −80 °C until needed.
The respective activities of β-site APP-cleaving enzyme (BACE1)/β-S
and of γ-S were measured in cell lysates (30–50 μg) and the results
were expressed as speciﬁc activity (means ± SEMs of ΔF μg−1 pro-
tein pertaining to each experimental group) (for further details see
[23]). To establish the speciﬁcity of the observed γ-S activity addi-
tional parallel control assays were carried out using the γ-S inhibitor
XII (Z–IL–CHO) (8.5 μM; Calbiochem-Millipore).
2.8. Assays of proteasomal proteolytic activities
They were performed according to Beyette et al. [54]. Astro-
cytes' lysates (10 μg) were incubated at 37 °C with the ﬂuorogenic
substrates succinyl-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC; 50 μM),
t-Butoxycarbonyl-Leu-Arg-Arg-AMC (Boc–LRR-AMC; 100 μM), and
Benzyloxycarbonyl-Leu-Leu-Glu-βNaphthylamide (Z–LLE-βNA;
400 μM) (Enzo Life Sciences AG, Switzerland). The results were
expressed as speciﬁc activity (means ± SEMs of ΔF μg−1 protein
pertaining to each experimental group).
2.9. Assay of NO released into cell-conditioned growth media
The secreted amount of NO was deduced from the concentrations of
NO's two stable oxidation products, NO2− and NO3−, in the media. The
ﬂuorometric method we used is based upon the reaction of NO2− with
2,3-diamino-naphthalene (DAN; Sigma-Aldrich) to form the ﬂuorescent
1-(H)-naphthotriazole [37,38,55]. Nitrates in the mediumwere reduced
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Roche, Milan) in the presence of 10 mM FAD and 100 mM NADPH.
Any residual NADPH was then oxidized with lactate dehydrogenase
(10 U ml−1) in the presence of 10 mM sodium pyruvate. The total
NO2− concentration was then determined in 50 μl samples of the culture
supernatants that were brought up to 100 μl with doubly deionized
water. Freshly prepared DAN (10 ml of a 0.05 mg ml−1 solution in
0.62 M HCl) was added to these diluted samples, and after a 10 min in-
cubation at 20 °C in the dark, the reactionwas stoppedwith 5 μl of 2.8 N
NaOH. The amount of 1-(H)-naphthotriazole formed was measured
ﬂuorometrically at excitation and emission wavelengths of 365 nm and
450 nm, respectively. Samples of fresh culture medium were used as
blanks to correct for background NO2− and NO3− concentrations in the
medium (~7 μM). NO2− concentrations were calculated from a standard
curve using NaNO2.
2.10. Enzyme-linked immunosorbant assays (ELISAs) of secreted Aβ42
and Aβ40 in cell-conditioned growth media samples
Quantiﬁcations of Aβ42 and Aβ40 released into in cell-conditioned
growth media samples were carried out by means of speciﬁc Human/
Rat ELISA Kits, High-Sensitive (both from Wako, Japan). The Aβ42 kit
has a dynamic range of 0.1–20.0 pmol L−1 and a sensitivity of
0.024 pmol L−1. This kit uses the monoclonal antibody BNT77, the
epitope of which is Aβ11–28 and the monoclonal antibody BC05, which
speciﬁcally detects the C-terminal portion of Aβx–42. The Wako Aβ42
ELISA kit is 700-fold more sensitive than the SIG-38956 ELISA kit
(Covance) we previously used [23]. The Aβ40 kit has a dynamic range
of 1.0–100 pmol L−1 and a sensitivity of 0.049 pmol L−1. This kit uses
the monoclonal antibody BNT77 (v. supra) and the monoclonal
antibody BA27, which speciﬁcally detects the C-terminal portion ofFig. 1. The total CaSR protein complement of cultured astrocytes is transiently increased b
fAβ25–35 + NPS 2143, only momentarily reduced by NPS 2143 alone, and totally unaffected
untreated (0 h) controls according to the experimental treatments (displayed at the top). LC, l
bands in the immunoblots for each time point and experimental treatment. Points in the curve
fAβ25–35: F = 9.459, p = 0.002; Holm–Sidak's test vs. 0 h (controls): *, p = 0.009. fAβ25–35 + N
least at each marked point. NPS 2143: F = 9.833, p b 0.001; Holm–Sidak's test vs. 0 h (controAβx–40. Brieﬂy, the astrocytes' and HCN-1A neurons' conditioned
media samples were added with a protease inhibitor cocktail (Roche)
and centrifuged for 10 min at 13,000 rpm to remove any cellular debris.
Supernatants were tested in triplicate according to the manufacturer's
protocol.
2.11. Statistical analysis
The data were analyzed using SigmaStat 3.5™ Advisory Statistics
for Scientists (Systat Software). For immunoblotting, bands' densito-
metric data were normalized to corresponding loading control
(lamin B1) bands and next analyzed by one-way ANOVA. When the
ANOVA's upshot was signiﬁcant (p b 0.05), post hoc Holm–Sidak's
test was used for comparisons vs. 0 h (untreated controls) values.
Null hypotheses were rejected when p > 0.05.
3. Results
3.1. Total CaSR protein expression is modulated by exogenous
fAβ25–35 + calcilytic NPS 2143 or by NPS 2143 alone but is not changed
by calcimimetic NPS R-568 alone in adult human astrocytes
Since the CaSR is expressed by adult human astrocytes [37,38] and is
an Aβs target [34,38], we asked whether a fAβ25–35-triggered CaSR sig-
nalling may contribute to the fAβ25–35-elicited stimulation of endoge-
nous Aβ42 production, and intracellular accrual we previously reported
[23]. As a ﬁrst step, we checked whether, as suggested by the work of
Huang and Breitweiser [56], a calcilytic by itself or added to fAβ25–35 or
a calcimimetic alone might affect total CaSR protein expression.
The CaSR protein was discretely expressed in the untreated astro-
cytes, and its total amount transiently increased peaking at 48 hy the exposure to exogenous fAβ25–35, yet quickly and then persistently decreased by
by NPS R-568. (A) Typical immunoblots showing the changes in total CaSR protein vs.
oading control (i.e., lamin B1). (B) Densitometric assessments of the speciﬁc CaSR protein
s are means ± SEMs of 4 separate experiments with 0 h values normalized to 1.0. ANOVA:
PS 2143: F = 26.807, p b 0.001; Holm–Sidak's test vs. 0 h (controls): *, p = 0.0000157 at
ls): *, p = 0.00176 at least at each marked point. NPS R-568: F = 0.125, p = 0.944.
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trast, the CaSR total protein levels fell rapidly and then were kept
steadily reduced between 24 h and 72 h (−60/−65%, p b 0.001) in
the NPS 2143 + fAβ35–25-exposed astrocytes. Conversely, a transient
decrease (−30%, p b 0.05) of the total CaSR protein was induced at
24 h in astrocytes treated with NPS 2143 alone (Fig. 1A,B). Finally,
the calcimimetic NPS R-568 given by itself did not change the basal
CaSR total protein levels in the astrocytes (Fig. 1A,B).
Thus, such observations revealed a speciﬁc Aβ/CaSR interaction
that could be signiﬁcantly reduced by NPS 2143, which would cause
the CaSR to shift into a proteasomal protease-targeting conformation
[37,47,48]. Therefore, we felt entitled to further investigate the effects
of fAβ25–35 + NPS 2143 on the metabolism of the two main Aβ spe-
cies in the adult human astrocytes.3.2. Stimulation of both secretases' activities by exogenous fAβ25–35 is not
hindered adding NPS 2143 in adult human astrocytes
Wepreviously reported that the activities of both the Aβ-generating
secretases were signiﬁcantly (p b 0.001) stimulated by exogenous
fAβ25–35 but not by its reversemer Aβ35–25 [23]. Thus,weﬁrst conﬁrmed
such results and next assessed the effects of adding NPS 2143. Thus,
while exogenous fAβ25–35, increased both BACE1/β-S and γ-S activities
(Fig. 2A,B), in the fAβ25–35 + NPS 2143-exposed astrocytes the
time-related γ-S activity curve rose just like it did when fAβ25–35 was
given alone, thereby suggesting that it bore no relation to Aβ/CaSR sig-
nalling (Fig. 2A,B). Conversely, adding NPS 2143 delayed from 24 h to
48 h the surge of BACE-1/β-S activity otherwise elicited by fAβ25–35
(Fig. 2A,B). But, notwithstanding this delay, the total stimulated
BACE-1/β-S activity over the ﬁrst 72 h, as measured by the area under
the curve, increased marginally (+14.4%, p = 0.045) in the NPS
2143 + fAβ25–35-treated with respect to the fAβ25–35 alone-exposed
astrocytes. Hence, the deep and persistent negative modulation of the
total CaSR protein expression by NPS 2143 + fAβ25–35 (Fig. 1A,B) didFig. 2. The activities of BACE1/β-S and of γ-S surge in adult human astrocytes treated with fAβ
reversemer Aβ35–25 is ineffective on the basal activity of either secretase. (A) The BACE1/β-S p
respect to that induced by fAβ25–35 alone. Notably, the total (0–72 h) activity of BACE1/β-S asme
exposed to NPS 2143 + fAβ25–35 vs. fAβ25–35 by itself. Points on the curves are means ± SEMs o
p b 0.001; Holm–Sidak's test vs. 0 h (controls) *, p b 0.03 at least for each time point. NPS 2143 +
for each point. Reversemer Aβ35–25: F = 0.048, p = 0.986. (B) Astrocytes' γ–S activity similarly p
of 4 separate experiments with 0 h values normalized as 1.0. ANOVA: fAβ25–35 + NPS 2143: F =
Reversemer Aβ35–25: F = 0.007, p = 0.999.not curtail the Aβ25–35-induced increases in the activity of each
secretase and hence the intensiﬁed endogenous production of Aβs.3.3. Calcilytic NPS 2143 speciﬁcally suppresses the fAβ25–35-driven surplus
intracellular accrual and secretion of endogenous Aβ42 by adult human
astrocytes
Just as we previously observed [23], densitometric analysis of
the several speciﬁc oligomeric Aβ42 bands in the immunoblots
showed that between 0 h and 48 h the total intracellular levels of
endogenous Aβ42 peptides more than tripled in the fAβ25–35
(20 μM)-treated astrocytes vs. the 0 h (untreated) controls
(Fig. 3A,B). In sharp contrast, when the astrocytes were treated
with NPS 2143 + fAβ25–35 no signiﬁcant (p > 0.05) intracellular
accrual of Aβ42 obtained at any time point examined (Fig. 3A,B).
On the other hand, when given each by itself, the calcilytic NPS
2143 and the calcimimetic NPS R-568, did not change (p > 0.05)
between 0 h and 72 h the astrocytes' basal intracellular levels of
Aβ42 (Fig. 3A,B).
To better gauge the stimulatory effects of exogenously administered
fAβ25–35 on the de novoproduction of endogenousAβ42 (andof Aβ40: see
Section 3.4), we reckoned its release into the medium. Thus, between
0 h and 72 h the fAβ25–35 alone-driven intracellular accrual of endoge-
nous Aβ42 went together with an increasing secretion of Aβ42 that
stayed well above the basal values (Fig. 3A–C). At variance with previ-
ous results [23], in this work we reproducibly detected this Aβ42 secre-
tion through the use of a very highly sensitive and speciﬁc Aβ42 ELISA
kit (see for details the Materials and methods section). In sharp con-
trast, adding NPS 2143 to fAβ25–35 treatment steadily kept the secreted
amount of endogenousAβ42 at basal (i.e. control) levels (Fig. 3C). On the
other hand, calcimimetic NPS R-568 given alone signiﬁcantly raised the
secreted amount of Aβ42 without changing its basal intracellular con-
tents (Fig. 3A,B,C). Therefore, calcilytic NPS 2143 fully suppressed the
fAβ25–35-induced huge intracellular accumulation and surplus secretion25–35 and the addition of NPS 2143 only delays the peak of BACE1/β-S activity. Conversely,
eak activity shifts from 24 h to 48 h in astrocytes exposed to NPS 2143 + fAβ25–35 with
asured by the area under the curve is marginally greater (+14.4%, p = 0.045) in astrocytes
f 4 separate experiments with 0 h values normalized as 1.0. ANOVA: fAβ25–35, F = 27.913,
fAβ25–35: F = 22.899, p b 0.001; Holm–Sidak's test vs. 0 h (controls): *, p b 0.005 at least
eaks by 48 h of exposure to fAβ25–35 + NPS 2143. Points on the curves aremeans ± SEMs
35,896, p b 0.001; Holm–Sidak's test vs. 0 h (controls): *, p b 0.007 at least for each point.
Fig. 3. Changes in the adult human astrocytes' intracellular and secreted amounts of endogenous Aβ42 according to the several experimental treatments. (A) Typical immunoblots
revealing the changes in intracellularly accrued endogenous Aβ42 peptides/oligomers vs. untreated (0 h) controls according to the experimental treatments (displayed at the top).
Note the denser bands elicited by fAβ25–35 by itself. Conversely, reversemer Aβ35–25 is totally ineffective as previously demonstrated [23] (but not shown here). LC, loading control
(i.e., lamin B1). (B) Densitometric assessments of the whole sets of intracellular Aβ42 bands in the immunoblots for each time point and experimental treatment. Points in the curves
are means ± SEMs of 4 separate experiments, with 0 h values normalized as 1.0. ANOVA: fAβ25–35, F = 16.574, p b 0.001. Holm–Sidak's test vs. 0 h (controls): *, p b 0.006 at least,
at each time point. fAβ25–35 + NPS 2143: F = 0.952, p = 0.446. NPS 2143: F = 3.222, p = 0.162. NPS R-568, F = 1.149, p = 0.360. WB, Western immunoblots. (C) The secreted
amounts of endogenous Aβ42 peptides is increased by the exposure to fAβ25–35 or to the calcimimetic agent NPS R-568, but does not change when NPS 2143 is associated with
fAβ25–35 or given by itself. The various cell-conditioned media samples were processed and assayed with a highly sensitive ELISA kit as indicated in the Materials and methods sec-
tion. Points on the curves are means ± SEMs of 4 separate experiments. ANOVA: fAβ25–35: F = 35.152, p b 0.001; Holm–Sidak's test vs. 0 h (controls): *, p b 0.0000242 at least, at
each point. fAβ25–35 + NPS 2143: F = 0.820, p = 0.507; NPS 2143: F = 3.558, p = 0.048; NPS R-568: F = 12.836, p b 0.001; Holm–Sidak's test vs. 0 h (controls): *, p b 0.0223 at
least at each time point.
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calcimimetic NPS R-568 by itself simply raised the Aβ42 secretion rate.
3.4. Calcilytic NPS 2143 slightly reduces the accrual but discretely
increases the secretion of endogenous Aβ40 in fAβ25–35-exposed adult
human astrocytes
Aβ40 is the other main peptide isoform produced by the sequential
activities of BACE-1/β-S and γ-S [1–3]. This warranted the parallel inves-
tigation of Aβ40 metabolism in the NPS 2143 + fAβ25–35-exposed astro-
cytes. Thus, between 24 h and 48 h the intracellular levels of Aβ40 werealmost doubled (p b 0.001 vs. 0 h) in the fAβ25–35 alone-treated astro-
cytes and then started falling (Fig. 4A,B). At variance with what we ob-
served with Aβ42, adding NPS 2143 to fAβ25–35 only partially decreased
at 24 h and 72 h the fAβ25–35-induced intracellular accrual of Aβ40
(Fig. 4A,B). In fact, the total (0 h–72 h) rises in Aβ40 intracellular accu-
mulation vs. basal (untreated) levels, as assessed by the areas under
the respective curves, were +73.4% in the fAβ25–35-exposed astrocytes,
and+51.3% in the NPS 2143 + fAβ25–35-treated astrocytes, respectively
(p b 0.001 in both instances vs. 0 h controls). On the other hand, prelim-
inary evidence also indicated that when given alone NPS 2143 did not
change the basal intracellular levels of Aβ40 (not shown).
Fig. 4. Changes in the intracellular and secreted amounts of endogenous Aβ40 peptides by adult human astrocytes' treated with NPS 2143 ± fAβ25–35. (A) Typical immunoblots
revealing the increases in intracellularly accrued endogenous Aβ40 peptides/oligomers vs. untreated (0 h) controls according to the experimental treatment (displayed at the
top). Note the denser bands elicited by the exposure to fAβ25–35 by itself. Adding NPS 2143 to the fAβ25–35 only slightly reduces the intracellular accrual of Aβ40 peptides during
the time lag considered. LC, loading control (lamin B1). (B) Densitometric evaluations of the whole sets of intracellular Aβ40 bands in the immunoblots for each time point and
experimental treatment. Points in the curves are means ± SEMs of 4 separate experiments, with 0 h values normalized as 1.0. ANOVA: fAβ25–35, F = 39.074, p b 0.001. Holm–
Sidak's test vs. 0 h (controls):*, p b 0.003 at least, at each time point considered. fAβ25–35 + NPS 2143: F = 29.331, p b 0.001; Holm–Sidak's test vs. 0 h (controls): p b 003 at
least at each point. (C) The secretion of endogenous Aβ40 peptides by the astrocytes is increased by an exposure to fAβ25–35 + NPS 2143, whereas is left unchanged by fAβ25–35
by itself. The cell-conditioned media samples were processed and assayed with a highly sensitive and speciﬁc ELISA kit as indicated in the Materials and methods section. Points
on the curves are means ± SEMs of 4–8 separate experiments. ANOVA: fAβ25–35: F = 0.888, p = 0.446; NPS 2143 + fAβ25–35: F = 5.076, p = 0.012; Holm–Sidak's test vs. 0 h
(controls): *, p b 0.0171 at least, at each point. fAβ25–35 vs. NPS 2143 + fAβ25–35, F = 3.813, p b 0.008; Holm–Sidak's test vs. 0 h (controls): p b 0.003 at least at each time
point. (D) Secreted Aβ42/Aβ40 ratio values signiﬁcantly shift in favour of Aβ42 in the growth media of fAβ25–35-treated astrocytes, but are kept at values signiﬁcantly lower than
control (0 h) ones in the media of NPS 2143 + fAβ25–35-exposed astrocytes. Bars are means ± SEMs of at least 4 separate experiments. ANOVA: fAβ25–35, F = 22.445, p b 0.001;
Holm–Sidak's test vs. 0 h (controls): *, p b 0.0002 at least at each point. fAβ25–35 + NPS 2143: F = 9.958, p b 0.001; Holm–Sidak's test vs. 0 h (controls): *, p b 0.006 at least at
each point.
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lower amounts than Aβ42's. But, again at variance with Aβ42, in the
growth media of the fAβ25–35-treated astrocytes the quantities of Aβ40
secreted between 0 h and 72 h were not signiﬁcantly changed
(p > 0.05) vs. untreated controls. However, adding NPS 2143 tofAβ25–35 increased by about 25% (p b 0.05) the secreted amounts of
Aβ40, (Fig. 4C) whereas under this respect NPS 2143 by itself was
ineffective (data not plotted).
It is well established that increases in Aβ42/Aβ40 ratio values are held
as importantmarkers of AD [1–3] Thus, an exposure to fAβ25–35 by itself
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values from 1.16 to 1.86 (p b 0.001) in the astrocyte-conditioned
growth media (Fig. 4D). However, during the same time lag, adding
NPS 2143 to the fAβ25–35 treatment kept the Aβ42/Aβ40 ratio values al-
ways below the starting value (0.79 at 72 h, p b 0.001) (Fig. 4D). Hence,
NPS 2143 prevented from unduly escalating the secreted Aβ42/Aβ40
ratio values in the conditionedmedia of adult human astrocytes treated
with fAβ25–35.3.5. Astrocytes' proteasomal chymotrypsin-like activity is changed by
exogenous fAβ25–35 + NPS 2143
Intracellular Aβ42 and Aβ40 oligomers have been reported to selec-
tively inhibit the proteasome and hence to promote their own intra-
cellular accumulation [57]. Hence, we asked whether exogenous
fAβ25–35 while stimulating the activities of BACE1/β-S and γ-S
would concurrently inhibit proteasomal enzymatic activities in the
adult human astrocytes. Our results showed that the three enzymatic
activities of the proteasome were differently affected in the fAβ25–35
alone-exposed cells. The caspase-like and trypsin-like activity levels
did not change between 0 and 72 h (p > 0.05, data not plotted).
Conversely, the chymotrypsin-like (20S) activity increased slowly
peaking by 72 h (+39.9%, p b 0.001) (Fig. 5). But in the NPS
2143 + fAβ25–35-exposed astrocytes, an earlier sharp surge in the
chymotrypsin-like (20S) activity obtained, which peaked by 24 h
(+59.3%, p b 0.001) when CaSR's total protein had reached its lowest
level and the intracellular Aβ42's and Aβ40's levels were still on the
rise (cf. Figs. 1B, 3B, and 4B). Thereafter this activity fell reaching by
72 h levels signiﬁcantly lower (−34%, p b 0.01) than at 0 h (Fig. 5).
On the contrary, adding NPS 2143 to the fAβ25–35 treatment did not
change between 24 h and 72 h the proteasomal trypsin-like activity
while marginally lessening the proteasomal caspase-like activity (data
not shown). Notably, the human proteasomal chymotrypsin-like
(h20S) activity was reported to degrade small intracellular Aβ42 oligo-
mers acting as its own competitive substrates [58]. However, according
to our ﬁndings, this enhanced chymotrypsin-like proteolytic action was
restricted to the ﬁrst 24–36 h in the NPS 2143 + fAβ25–35-treatedFig. 5. The proteasomal chymotrypsin-like (20 S) activity marginally increases during the
ﬁrst 48 h but rises signiﬁcantly by 72 h in fAβ25–35-exposed adult human astrocytes. Con-
versely, the fAβ25–35 + NPS 2143 treatment triggers a sharp peak of 20S activity at 24 h
followed by a drop to sub-basal levels by 72 h. The chymotrypsin-like (20 S) activity
was assayed on whole protein extracts from astrocytes as described in the Materials and
methods section. Points on the curves are means ± SEMs of 4 separate experiments.
ANOVA: fAβ25–35: F = 6.539, p = 0.007; Holm–Sidak's test vs. 0 h (controls): *, p =
0.000747. fAβ25–35 + NPS 2143: F = 45.514, p b 0.001; Holm–Sidak's test vs. 0 h
(controls): *, p = 0.00310 at the two points involved.astrocytes. Therefore, the later remarkable reductions in the intracellu-
lar levels of endogenous Aβ42 and Aβ40 we observed (cf. Figs. 3 and 4)
may have been caused by other Aβ-degrading proteases (AβDPs) [59].
3.6. Exogenous fAβs-driven increases in astrocytes' NO release are
suppressed by NPS 2143 or by U0126 and rescued by adding
tetrahydrobiopterin (BH4)
A clue to one of the other AβDPs involved is the ability of fAβ25–35
and of fAβ1–42, but not of reversemer Aβ35–25, to stimulate the produc-
tion and release, from 48 h onwards, of likewise huge amounts of NO by
the adult human astrocytes (Fig. 6). But, adding NPS 2143 or the MEK
inhibitor U0126 to the fAβ25–35 or fAβ1–42 treatment fully suppressed
this intensiﬁed NO release (Fig. 6). Then again, adding exogenous BH4
to NPS 2143 or U0126 + fAβ25–35 or fAβ1–42 treatment fully rescued
the excess release of NO from inhibition (Fig. 6). These results indicate
the involvement of Aβ/CaSR interactions and downstream MEK/ERK
signalling in the increased production of BH4, the cofactor needed to di-
merize and activate NOS-2, by the GTP cyclohydrolase-1 (GCH-1)
[60,61]. Such ﬁndings are relevant to intracellular Aβ42 and Aβ40 degra-
dation because NO overproduction is known to block the Aβ-degrading
IDE, whereas effectively preventing NO overproduction preserves IDE's
activity [62].
3.7. sAβ25–35-driven surplus secretion of endogenous Aβ42 by astrocytes
is speciﬁcally blocked by NPS 2143 whereas a discretely increased
secretion of Aβ40 obtains with sAβ25–35 + NPS 2143
At present, sAβ42 oligomers are held as perhaps the most important
cell damaging forms of Aβs [1–3]. Therefore, wewere enticed to test the
effects of sAβ25–35 + NPS 2143 on Aβ42 and Aβ40 secretion by the adultFig. 6. The release of NO by adult human astrocytes is similarly increased by the
exposure to Aβ25–35 or Aβ1–42 (both in ﬁbrillar form) but is totally prevented by the
concurrent addition of calcilytic NPS 2143 or of U0126 (a MEK/ERK inhibitor). Con-
versely, reversemer fAβ35–25 is completely ineffective. The addition of BH4, a cofactor
dimerising and activating NOS-2, overcomes the NPS 2143- or of U0126-elicited blocks
of BH4 production by GCH1 and hence of NO over-production and release. NO levels in
the respective growth media samples were assessed as detailed in the Materials and
methods section. Bars are means ± SEMs of 4 distinct experiments. ANOVA: F =
5.065, p = 0.002; Holm–Sidak's test vs. CTR (0 h controls): *, p b 0.00964 at least for
each marked bar.
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enous Aβ42 increased by about 2.45-fold (p b 0.001) in the sAβ25–35
alone-exposed astrocytes, to start slowly falling thereafter. Most re-
markably, this Aβ42 over-secretion was totally suppressed by addingFig. 7. Changes in the amounts of Aβ42 and Aβ40—and in the corresponding Aβ42/Aβ40 ratio
(for experimental details see theMaterials andmethods section). (A) The secretion of Aβ42 is sig
is totally blotted out by the daily pre-treatment with NPS 2143 (100 nM). Points in the curves a
Holm–Sidak's test vs. 0 h (controls): *, p b 0.0001 at least; sAβ25–35 + NPS 2143: F = 0.695,
sAβ25-35 ± NPS 2143. Points in the curves are means ± SEMs of 4–8 separate experiments. AN
both treatments, Holm–Sidak's test vs. 0 h (controls): *, p b 0.004 at least. (C) Secreted Aβ4
what lower than control (0 h) values by adding NPS 2143 to sAβ25–35 treatment.. ANOVA:
values: *, p = 0.00001 at least; sAβ25–35 + NPS 2143: F = 1.687, p = 0.187.NPS 2143 to the sAβ25–35 treatment (Fig. 7A). Conversely, between
48 h and 72 h sAβ25–35 alone discretely increased (+25%, p b 0.01)
the amount of Aβ40 secreted by the adult human astrocytes, and adding
NPS 2143 to sAβ25–35 elicited between 0 h and 48 h a nearly steadyvalues—secreted by adult human astrocytes after treatment with sAβ25–35 + NPS 2143
niﬁcantly increased following a daily exposure to sAβ25–35 (2.0 μM), but thismassive surge
re means ± SEMs of 4–8 separate experiments. ANOVA: sAβ25–35, F = 89.384, p b 0.001;
p = 0.568. (B) The secreted amounts of Aβ40 are much less increased by an exposure to
OVA: sAβ25–35, F = 12.707, p b 0.001; sAβ25–35 + NPS 2143: F = 11.306, p b 0.001; for
2/Aβ40 ratio values are signiﬁcantly raised by sAβ25–35 alone but kept close to or some-
sAβ25–35, F = 83.114, p b 0.001; Holm–Sidak's test vs. 0 h (controls) Aβ42/Aβ40 ratio
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detailed changes in Aβ42 and Aβ40 released amounts, the Aβ42/Aβ40
ratio values also changed remarkably: adding sAβ25–35 alone increased
the Aβ42/Aβ40 ratio values from 2.0-to-1.7-fold between 24 h and 72 h
(p b 0.0001 at least in all instances), whereas adding NPS
2143 + sAβ25–35 steadily kept the Aβ42/Aβ40 ratio values below or
close to control (0 h) ones (p > 0.05 at all time points) (Fig. 7C). There-
fore, sAβ25–35 was more effective than fAβ25–35 in triggering the
CaSR-mediated Aβ42 secretion and adding NPS 2143 speciﬁcally and to-
tally curtailed the Aβ42 oversecretion. In addition, sAβ25–35 discretely
increased Aβ40 secretion whereas fAβ25-35 did not (cf. Figs. 4C and
7B). On its own part, NPS 2143 modestly enhanced astrocytes' Aβ40 se-
cretion when added to the fAβ25–35 or sAβ25–35 (Fig. 7B). Consequently,
adding NPS 2143 kept Aβ42/Aβ40 ratio values below starting ones inde-
pendently of the involvement of sAβ25–35 or fAβ25–35.3.8. Exogenous fAβ25–35 and sAβ25–35-driven death of human cortical
HCN-1A neurons is fully prevented by NPS 2143
Since fAβ25–35 (20 μM) [25] and fAβ40 (25–50 μM) [63] have proven
to be neurocytotoxic, we askedwhether the cell death-inducing activity
of Aβs might be hindered by NPS 2143. As expected, fAβ25–35 by itself
caused a signiﬁcant fraction of the HCN-1A neurons to die and disinte-
grate between 0 h and 72 h, whereas it did not impact at all on astro-
cytes' survival (Fig. 8A,B). Super-imposable results, i.e. fractional
neuronal death and no effect on astrocytes viability, obtained when
either cell type was daily exposed to sAβ25–35 (2 μM; data not plotted).
Remarkably, adding NPS 2143 fully prevented this f- or sAβ25–35-elicited
death of a fraction of the HCN-1A neurons (Fig. 8A and data not shown).
On the other hand, NPS 2143 by itself exerted no effect on the survival ofFig. 8. The time-related numbers/mm2 or culture disk of proliferatively quiescent normal hum
NPS 2143 alone. (A) During the time lag considered astrocytes' survival was not affected by
means ± SEMs of 4 separate experiments. ANOVA: fAβ25–35, F = 0.0436, p = 0.979; fAβ25–3
deadly effect of an exposure to fAβ25–35 on a fraction of the HCN-1A neurons is fully prevented b
bers. Points in the curves are means ± SEMs of 4 separate experiments. ANOVA: fAβ25–35, F
p b 0.001 at least. fAβ25–35 + NPS 2143: F = 0.172, p = 0.914. NPS 2143: F = 0.0584, p = 0otherwise untreated HCN-1A neurons or astrocytes or of fAβ25–35- or
sAβ25–35-treated astrocytes (Fig. 8A,B and data not plotted). Hence, NPS
2143had the noteworthy beneﬁcial property of preserving neuronal sur-
vival in the presence of fAβ25–35 or sAβ25–35.3.9. Calcilytic NPS 2143 speciﬁcally suppresses the fAβ25–35-driven
surplus secretion of endogenous Aβ42 by HCN-1A neurons
Proliferatively quiescent, untreated HCN-1A neurons were poly-
morphic cells endowedwith cytoplasmic branches of variable length
(Fig. 9A, panels Ctr). But, the HCN-1A neurons surviving an exposure
to fAβ25–35 exhibited somata of increased sizes endowed with more
numerous, longer, and thicker cytoplasmic processes (Fig. 9A, panel
fAβ25–35). Immunocytochemical analysis showed that the anti-Aβ42
antibody decorated a restricted number of cytoplasmic round bodies
(vesicles) in the untreated HCN-1A neurons (Fig. 9A,B, panels Ctr).
However, in the 48 h fAβ25–35-exposed neurons the anti-Aβ42 anti-
body decorated increased numbers of vesicles that had spread
throughout the somata and the entire length of their branches
(Fig. 9A, panel fAβ25–35 with inserts 1–3 magniﬁed on the right).
Moreover, fAβ25–35-treated HCN-1A neurons released signiﬁcantly
higher amounts of Aβ42 into the growth medium than did their
untreated (0 h) counterparts (Fig. 9C). Treating the HCN-1A neurons
with fAβ25–35 + NPS 2143 restricted the Aβ42-positive vesicles to
the peripheral portions of the somata, leaving a perinuclear zone,
probably corresponding to the site of the Golgi apparatus/trans-Golgi
network (TGN) and inner endosomes, nearly completely free of
Aβ42-positive vesicles just as mostly free of such vesicles also were
the cellular processes (Fig. 9A and B, panel NPS 2143 + fAβ25–35
with inserts 1–3 magniﬁed on the right). Most important, addingan cerebral cortex astrocytes and HCN-1As neurons exposed to fAβ25–35 + NPS 2143 or to
exogenous fAβ25–35 + NPS 2143 or by NPS 2143 given alone. Points in the curves are
5 + NPS 2143: F = 0.0612, p = 0.979; NPS 2143: F = 0.0805, p = 0.969. (B) The early
y adding NPS 2143, whereas NPS 2143 by itself does not impinge on viable neurons' num-
= 10.626, p b 0.001; Holm–Sidak's test vs. 0 h (control) HCN-1A neurons numbers: *,
.981.
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Aβ42 secretion otherwise caused by fAβ25–35 by itself, thereby hold-
ing the secreted amounts of endogenous Aβ42 at starting (0 h) values
(Fig. 9C). Therefore, NPS 2143 signiﬁcantly altered the intracellular
distribution of the Aβ42-positive vesicles and thereby kept the secre-
tion rates of endogenous Aβ42 at control levels (Fig. 9C).
Immunoﬂuorescence analysis showed that a few irregularly
shaped bodies were decorated by the anti-Aβ40 antibody particularly
in the perinuclear cytoplasm of untreated HCN-1A neurons (Fig. 10,
panel Ctr). A 48 h exposure to fAβ25-35 increased the numbers of the
Aβ40-positive bodies which spread to the whole somata and their pro-
cesses (Fig. 10, panel fAβ25-35). Adding NPS 2143 to fAβ25–35 did not
change 48 h later the intracellular distribution of Aβ40-positive bodies
with respect to fAβ25–35 by itself (Fig. 10, panel NPS 2143 + fAβ25–35).
Finally, the secreted amounts of Aβ40 did not differ in the growth
media of untreated controls vs. NPS 2143 + fAβ25–35-exposed neurons
(Fig. 10, panel ELISA). Thus, at variancewith Aβ42 secretion, Aβ40 release
was not affected by adding NPS 2143 to fAβ25–35 treatment.
3.10. Calcilytic NPS 2143 speciﬁcally suppresses the sAβ25–35-driven
secretion of endogenous Aβ42 by HCN-1A neurons
Finally,we tested the effects of sAβ25–35 + NPS 2143 on theHCN-1A
neurons. Adding sAβ25–35 increased 48 h later the secreted amount
(+46%, p b 0.001) of endogenous Aβ42 (Fig. 11A). But in the growth
media samples of neurons treated with NPS 2143 + sAβ25–35 the se-
creted amount of endogenous Aβ42 was at control levels (Fig. 11A). No-
tably, the untreated HCN-1A neurons secreted a 7-fold higher amount
of endogenous Aβ40 than of Aβ42, and Aβ40 secreted basal amounts
were not signiﬁcantly changed by adding sAβ25–35 + NPS 2143
(Fig. 11A,B). As a consequence, the Aβ42/Aβ40 ratio value increased
(+36%, p b 0.001) with respect to controls following the addition of
sAβ25–35 alone, but was brought back close to starting value when
NPS 2143was added to sAβ25–35. Hence, sAβ25–35 increased Aβ42 secret-
ed amounts, but adding the CaSR antagonist NPS 2143 speciﬁcally and
wholly annulled this sAβ25–35's stimulatory effect.
4. Discussion
4.1. The Aβ42 proxy Aβ25–35
As in previous works [23,25,53], here we challenged untransformed
cortical adult human astrocytes and HCN-1A neurons with Aβ25–35, an
Aβ42 proxy endowed with the aggregation-essential function key
Met35 [64]. This allowed us to easily assay the endogenously produced
and secreted Aβ42 and Aβ40 via very highly speciﬁc and sensitive
ELISA kits. Abundant lines of evidence indicate that Aβ25–35 holds all
the crucial properties of Aβ1–42, like ﬁbril formation, neurotropism,
induction of free radical generation, neurotoxicity, and the ability to
interact with various proteins, apolipoprotein E (apoE) included
[23,25,65–68]. Notably, fAβ25–35 is actually produced in human AD
brains but never in normal brains [22,69,70]. Reportedly, fAβ25–35
and fAβ1-42 elicit identical functional (e.g., p75NTR induction) and cy-
totoxic (e.g., apoptogenesis) effects in a panoply of experimental
models [25,65–71], which justiﬁes the widespread experimental
use of Aβ25–35 for AD-related studies. We could validate the full
biopathological interchangeability between fAβ25–35 and fAβ1–42 in
cultured untransformed adult human astrocytes with respect to the in-
duction of NO overproduction/release, the triggering of the intranuclear
translocation of HIF-1α transcription factor, and of the consequent
synthesis/secretion of various VEGF-A isoforms ([53] and unpublished
results). The dose of fAβ25–35 used here was found to be themost effec-
tive one in previous studies [23,25,53]. Although atﬁrst sight itmight be
considered a high bolus, it should be taken stock of the fact that, at var-
iance with sAβs, only the Aβ molecules arrayed at the surface of theﬁbrils are allowed to interact with components of the cell plasmamem-
branes and they correspond to a tiny fraction of the total.
4.2. The CaSR, fAβ25–35, calcilytic NPS 2143, and calcimimetic NPS R-568
CaSR expression is a feature of all types of nerve cells in the mam-
malian brain [44,49]. In cultured adult human astrocytes CaSR expres-
sion is independent of the actual [Ca2+]e, but is conditioned by the
proliferative state, being signiﬁcantly higher in mitotic quiescience
than active cell division [37]. Previously, the Aβ-evoked degeneration
of hippocampal neurons was related to raises in cytosolic [Ca2+]i [50],
and the activation of Ca2+-permeable non-selective cation channels
by fAβ25–35 and fAβ1–40 was observed only in wild type (WT)
CaSR+/+ rats but not CaSR−/− rats [33]. Changes in CaSR expression
and degradation are among the mechanisms regulating intracellular
CaSR signalling. The present results show that the astrocytes' total
CaSR protein amount was transitorily increased (peak at 48 h) by
an exposure to fAβ25–35 alone, was unchanged by the CaSR agonist
NPS R-568 by itself, was ﬂeetingly decreased (with a through at
24 h) by the CaSR antagonist NPS 2143, and most important of all,
was quickly and permanently downregulated by coupling NPS 2143
with fAβ25–35. Breitweiser et al. [56] reported that NPS 2143 promot-
ed CaSR's stabilization in an “inactive” CaSR conformation at a check-
point located in the endoplasmic reticulum (ER); the “inactive” CaSR
would then be polyubiquitinylated by dorﬁn, an E3 ligase, and next
degraded by the proteasome [56]. This mechanism was probably op-
erating when NPS 2143 was given by itself and the fall in total CaSR
protein was transient. But the persistent decrease of the total CaSR
protein elicited by the fAβ25–35 + NPS 2143 is the likely upshot of a
more complex mechanism as under such circumstances the surge of
proteasomal chymotrypsin activity occurred only during the ﬁrst
48 h. Hence, some other mechanism (receptor endocytosis, lysosomal
digestion or else?) might have been involved and its identiﬁcation re-
quires further studies. The intense and persistent CaSR downregulation
in the NPS 2143 plus fAβ25–35-treated astrocytes would curtail the im-
pact of the Aβ-driven CaSR signalling on Aβs metabolism and secretion
and on NO over-production (see below and [37]). Conversely, CaSR allo-
steric agonist NPS R-568 did not change total CaSR protein levels in the
adult human astrocytes. Then again, Breitweiser et al. [56] reported
that NPS R-568 steadied the CaSR's protein thereby increasing its plasma
membrane and total cellular levels via an enhanced cotraslational stabi-
lization of its “active” conformation at the ER [56]. These differing results
may be explainedby the use by Breitweiser et al. of CaSR over-expressing
cells that were exposed to NPS R-568 for lengthy periods, whereas we
used untransformed adult human astrocytes thatwere only brieﬂy treat-
ed with the calcimimetic. In any event, our results stress the speciﬁc im-
pact of the Aβ/CaSR signalling on the intracellular accrual and secretion
of endogenous Aβ42 and its quite distinct modulation by a calcilytic or
a calcimimetic in the adult human astrocytes.
4.3. Aβ-driven CaSR signalling induces both Aβ42 and Aβ40 intracellular
accrual and increases Aβ42 secretion by both astrocytes and HCN-1A
neurons
According to the debated “amyloid hypothesis”, LOAD results from
the progressive intracellular and extracellular build-up of neurotoxic
Aβs presumably due to an ageing-related failure of their clearance
[1–4]. Yet, the mechanisms underlying Aβs accumulation in progres-
sively broader areas of AD brains and the respective contributions to
it by the various types of resident cells are still poorly deﬁned [72].
The concurrent binding/signalling-activating interactions between
sAβ oligomers and/or fAβ aggregates and various receptors at the
plasma membrane level, including the CaSR [25–34], are believed to
alter critical cellular functions and jeopardize neurons' viability. Pre-
viously, we showed that a speciﬁc interaction between the extracellu-
lar domain of p75NTR and exogenous Aβ25–35 or Aβ1–42 was necessary
Fig. 9. The changes in cytological features and intracellular distribution and secreted amounts of Aβ42 in HCN-1A neurons exposed for 48 h to fAβ25–35 + NPS 2143 vs. 0 h untreated
controls. These are merged pictures: DAPI-stained nuclei are blue; endogenous Aβ42 is yellow-green; blue clumps of extracellular fAβ25–35 are marked by a red *. (A) Top panel (Ctr).
Untreated HCN-1A neurons appear as sparse sizeable cells endowed with few short processes. Discrete numbers of cytoplasmic bodies containing endogenous Aβ42 are seen mostly
in the perinuclear cytoplasm being rare within the thereby poorly visible cellular processes. Lower left panel (fAβ25–35). The HCN-1A neurons that have survived a 48 h exposure to
fAβ25–35 exhibit somata of increased in size and processes of augmented numbers and length. The endogenous Aβ42-containing bodies have grown very abundant and are evenly
distributed inside the somata and processes; such bodies also collect at the tips of some processes (insets 1–3 are shown at a higher magniﬁcation on the right). Lower right panel
(fAβ25–35 + NPS 2143). In the NPS 2143 + fAβ25–35-treated neurons the endogenous Aβ42-positive bodies were conﬁned within the peripheral cytoplasm of the somata, but were
absent from a perinuclear area likely occupied by Golgi apparatus/TGN network and inner endosomes and also from the cellular processes, which consequently had become hardly
visible (insets 1–3 are shown at a higher magniﬁcation on the right, in which the arrowheads indicate the actual course of otherwise feebly visible cellular processes). Bar, 50 μm. Red *
indicates aggregates of fAβ25–35. (B) In untreated (Ctr) and fAβ25–35-exposed HCN-1A neurons endogenous Aβ42-positive bodies, although differing in numbers, are evenly distributed in
the perinuclear cytoplasm. Conversely, in fAβ25–35 + NPS 2143-exposed HCN-1A neurons a large perinuclear area, likely corresponding to the Golgi/TGN network and inner endosomal
compartment, is devoid of Aβ42-positive bodies, just as are the cellular processes. Corresponding insets 1–3, indicated with #, are shown at a highermagniﬁcation on the right. (C) Secre-
tion of endogenous Aβ42 is increased by the exposure of HCN-1A neurons to fAβ25–35, whereas it is kept at starting (basal) levels by treating with NPS 2143 + fAβ25–35 or with NPS 2143
alone. Experiments were carried out and secreted Aβ42was assayed as described in theMaterials andmethods section. Points in the curves aremeans ± SEMs of 4 separate experiments.
ANOVA: fAβ25–35: F = 13.845, p b 0.001; Holm–Sidak's test vs. 0 h (controls): *, p = 0.0106 at least. fAβ25–35 + NPS 2143: F = 1.188, p = 0.356. NPS 2143: F = 0.164, p = 0.918.
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Fig. 10. The intracellular distribution and secreted amounts of Aβ40 are not changed by a 48 h exposure of HCN-1A neurons to fAβ25–35 by itself or with NPS 2143. Panel Ctr. Only a
discrete number of Aβ40-positive bodies are detectable within the perinuclear cytoplasm of an untreated (control) HCN-1A neuron. Panel fAβ25–35. Anti Aβ40-antibody decorated
bodies have increased in numbers 48 h after an exposure to fAβ25–35, and evenly occupy the whole cytoplasm of the neurons revealing an intracellular accrual of the peptide. Panel
NPS 2143 + fAβ25–35. The picture is very similar to that of the fAβ25–35 alone panel indicating that NPS 2143 does not affect intracellular accrual and distribution of the Aβ40-positive bod-
ies. Red asterisks (*) indicate fAβ25–35 clumps that emit a blue ﬂuorescence andmaymask part of the neurons' bodies. Bar, 20 μm. Panel ELISA. The secreted amounts of Aβ40 are similar in
the growthmedia of untreated, fAβ25–35 and NPS 2143 + fAβ25–35-treated neurons. Experimentswere carried out and secreted Aβ40was assayed using a speciﬁc ELISA kit as described in
the Materials and methods section. Bars are means ± SEMs of 4 separate experiments. ANOVA: F = 0.070, p = 0.932.
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In the present study, we show through the use of NPS 2143, a CaSR al-
losteric antagonist [36,47,48], that a speciﬁc Aβ/CaSR interaction
drives the intracellular excess accumulation of both Aβ42 and Aβ40
and a hugely increased secretion of Aβ42 by both human cortical as-
trocytes and neurons, and moreover the death of a fraction of such
neurons. Intraneuronal accumulation of Aβ42, which preferentially
occurs in late endosomes and particularly in multivesicular bodies
(MVBs) [73], typically precedes the appearance of NFTs and the depo-
sition of senile Aβ plaques in the neuropil, and has been linked to the
pathogenesis of human AD [1–3]. Intracellular and extracellular ac-
cruals of soluble Aβ oligomers induce the loss of synapses and the
clinical manifestation of AD [1–3]. And although AD symptoms may
not tightly correlate with senile plaque burden, one should not over-
look the neurotoxic properties of extra- and intracellular insoluble
fAβ aggregates [74].
In keepingwith our previous report [23], the APP cleaving and Aβ40-
and Aβ42-producing activities of BACE-1/β-S and γ-S were signiﬁcantlystimulated by an exposure of adult human astrocytes to exogenous
fAβ25–35. Under this respect, the fAβ25–35-driven CaSR signalling might
have quickened only the happening of the BACE-1/β-S peak activity,
as suggested by its 24 h delay caused by adding the CaSR allosteric an-
tagonist NPS 2143 to the fAβ25–35 treatment. Conversely, the γ–S activ-
ity was totally independent of fAβ25–35-evoked CaSR signalling, as
indicated by the ineffectiveness of NPS 2143 in this regard. Several
mechanisms are known to control BACE-1/β-S activity, such as mRNA
transcription and protein translation, both of which are increased by
an exposure to fAβ25–35 in adult human astrocytes [23], posttranslation-
al protein modiﬁcation(s), complexing with other proteins, subcellular
and membrane microdomain distribution, and availability of a number
of substrates in addition to APP [75]. Even the signalling triggered by the
interactions of exogenous Aβs with several other membrane receptors
[25–33], besides the CaSR [34], might inﬂuence BACE-1/β-S and γ-S ac-
tivity levels. Further studies, some of which are under way in our labo-
ratory, will help reveal these complex interacting mechanisms in the
adult human astrocytes.
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dogenous Aβ42 and Aβ40 was mediated by the Aβ-driven CaSR signal-
ling as revealed by its speciﬁc suppression by CaSR antagonist NPS
2143 [36,47,48] by mechanisms not hindering the enhanced
BACE-1/β-S and γ-S activity. Indeed, initially a massive decrease of
the total CaSR protein and an as yet insigniﬁcant intracellular accu-
mulation of endogenous Aβ42 coincided with a transient surge of
the proteasome's chymotrypsin-like (20S) activity in the fAβ25–
35 + NPS 2143-exposed astrocytes. But, concurrently and/or at later
times, other mechanisms started operating to keep both the total
CaSR protein and endogenously overproduced Aβ42 at low levels
within the same cells. A delayed, slow activation of the proteasome's
chymotrypsin-like (20S) activity might have contributed to the later
post-peak fall of endogenous Aβ42 levels observed in both the previ-
ous [23] and present study in the astrocytes exposed to fAβ25-35
alone. Although the proteasome is sited in the cytosol, endoluminally
produced Aβ42 is known to passively diffuse from ER lumen into the
cytosol, where it is degraded by both the proteasome and IDE [35].
Several other Aβ42-degrading proteases (AβDPs) can powerfully
contribute to the control of intracellular Aβ42 levels so that the net
Aβ42 levels result from the balance between production and degrada-
tion rates. Moreover, Aβ42 proteolysis is negatively, and Aβ42
accumulation positively, inﬂuenced by ageing, endogenous inhibitors,
pharmacological blockers, and oxidative damage (see for references:
[59]). The ﬁnding that NPS 2143 only partially reduced the intracellu-
lar accrual of Aβ40 suggests that the disposal mechanism(s) of Aβ40
differ(s) from those of Aβ42 in astrocytes and remain to be identiﬁed
in their details.
It is relevant to recall here that human astrocytes partake to the
inﬂammatory component of AD (reviewed in [15]). Our results dem-
onstrate that, besides a cytokine mixture [37,61], exogenously added
sAβ40 [38], fAβ1–42, and fAβ25–35 (present results) quite similarly
stimulate, via the parallel induction of GCH-1 and NOS-2, the
overproduction/release of NO by adult human astrocytes [60]. In-
creased production of NO by inducible NOS-2 has been shown not
only to cause NO- and peroxynitrite-mediated neurotoxicity [38,61],
but even to reduce IDE, but not neprilysin, activity in APP/PS1 trans-
genic AD-model mice [62]. Most important, they also reveal thatFig. 11. Effects of a 48 h treatment with soluble (s)Aβ25–35 + NPS 2143 on the secreted amo
signiﬁcantly raised by a daily administration of sAβ25–35 (2 μM), but this stimulatory effec
performed and secreted amount of Aβ42 peptides assayed in the growth media samples by a
Bars are means ± SEMs of 3 separate experiments. ANOVA: F = 9.646, p = 0.013; Holm–Si
secreted by the HCN-1A neurons, which is 7-fold higher than that of Aβ42, is not signiﬁcantly
and Aβ42 assayed in the growth media samples by a speciﬁc and highly sensitive ELISA kit a
experiments. ANOVA: F = 4.021, p = 0.078.calcilytics like NPS 89626 or NPS 2143, just as the MEK inhibitor
U0126 ([61] and present results) block the increase in BH4 synthesis
by GCH-1 and, hence, NO overproduction by a BH4-dimerized/
activated NOS-2. Incidentally, U0126 and other MEK inhibitors have
been reported to decrease Aβ generation and secretion through a
secretase-independent drop of the AβPP C-terminal fragment
(β-CTF) levels in APPSwe-expressing human SH-SY5Y neuroblastoma
cells [76]. We are currently investigating whether this mechanism
might also operate in adult human astrocytes and postnatal neurons.
In summary, the beneﬁcial effects of NPS 2143 in fAβ25–35-exposed
adult human astrocytes are manifold, including a suppression of the
excess intracellular accumulation and of the surplus (but not basal)
secretion of endogenous Aβ42 and of their cytotoxic consequences, a
prevention of the noxious effects of NO overproduction/release, and
the preservation of the Aβ-cleaving activity of IDE and of other
AβDPs.
Under physiological conditions, in vivo neurons produce Aβ40 more
abundantly than Aβ42 [1–3] and the secreted amount of Aβ40 is about
10-fold that of Aβ42; moreover, their respective oligomers form via dif-
ferent routes [77,78]. Because of its high secretion rate Aβ40 was
reported to be poorly detectable within normal human, rat, and
mouse brain neurons [73]. At physiological (pM) levels Aβ40 acts as a
neurogenic factor [79], though it becomes cytotoxic at pathological con-
centrations in vitro [35,63]. Yet, undermorbid conditions in vivo, like the
early onset familial AD cases and in transgenic animal AD-models, the
Aβ42/Aβ40 ratio value shifts in favor of Aβ42 and small changes of such
values are believed to enhance the peptides' neurotoxicity [1–3]. Most
important, Aβ42 peptides form ﬁbrils faster than Aβ40; hence, Aβ42 is
deemed to be the most neurotoxic species [1–3]. Consequently, it was
important to deﬁne how the respective production and secretion of
Aβ40 and of Aβ42 behaved when cultured human adult astrocytes or
postnatal HCN-1A neurons were challenged with Aβ25–35 + NPS
2143. According to an early report, similar proportions of secreted
Aβ40 and Aβ42 were released by cultured brain rat cells of various
types [80]. Our present results show that both Aβ isoforms kept being
produced and secreted in vitro by either cell type: in the untreated as-
trocytes Aβ40 and Aβ42 were produced and secreted in closely similar
amounts, whereas HCN-1A neurons secreted 7-fold more Aβ40 thanunts of Aβ42 and Aβ40 peptides by HCN-1A neurons. (A) The secreted amount of Aβ42 is
t of sAβ25–35 is totally abolished by a co-treatment with NPS 2143. Experiments were
highly sensitive and speciﬁc ELISA kit as detailed in the Materials and methods section.
dak's test vs. control (Ctr) HCN-1A neurons: *, p b 0.001. (B) The basal amount of Aβ40
changed by treating the cells with sAβ25–35 + NPS 2143. Experiments were performed
s detailed in the Materials and methods section. Bars are means ± SEMs of 3 separate
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HCN-1A neurons the secreted amount of Aβ42 increased remarkably,
while that of Aβ40 did not change in the neurons but rose a little in
the astrocytes. Therefore, in both instances the Aβ42/Aβ40 ratio values
shifted neatly in favor of Aβ42. Here, we wish to stress that the CaSR
allosteric antagonist (calcilytic) NPS 2143 speciﬁcally suppressed the
Aβ25–35-elicited surplus secretion of Aβ42 by both neurons and astrocytes.
These ﬁndings strongly indicate that the metabolism of Aβ40 signiﬁ-
cantly diverges from that of Aβ42 in the adult human astrocytes and
HCN-1A neurons, as it happens in other cellularmodels [81]. Important-
ly, NPS 2143 did not hinder the basal low secretion rate of Aβ42, thereby
preserving its beneﬁcial physiological effects [5,6].
In keeping with other reports [23,82,83], on a 72 h basis fAβ25–35
and sAβ25–35 induced the death of a discrete fraction of the HCN-1A
neurons whereas they were innocuous for the astrocytes. Remark-
ably, adding NPS 2143 preserved the viability of all the fAβ25–35 or
sAβ25–35-exposed HCN-1A neurons. Hence, by negatively modulating
Aβ/CaSR signalling NPS 2143 exerts a valuable protective effect on the
survival of Aβ25–35-treated human cortical neurons in part by
preventing an excess accrual and secretion of the over-produced
endogenous Aβ42. Notably, immunocytochemical observations
showed that the distribution of the Aβ42-containing vesicles in the
HCN-1A neurons changed according to the treatment considered.
The Aβ42-positive vesicles became more abundant within the somata
and the whole length of their processes in the fAβ25–35-exposed neu-
rons. In the fAβ25–35 + NPS 2143-treated neurons the Aβ42-positive
vesicles were found at the periphery of the somata, but were missing
from a perinuclear region likely occupied by Golgi apparatus/TGN
network and inner endosomes. Because of this, the Aβ42-positive ves-
icles were largely missing even from the entire length of the neuronal
processes. Reportedly, in rat embryo (17 days) primary neuronal cul-
tures, Aβ42 and Aβ40 are mostly made within the TGN network and
next packaged inside post-TGN secretory vesicles; yet, Aβ42 is also
made and kept in an insoluble condition within the ER and the TGN
[84]. Aβ production after endocytosis of APP also happens in early
endosomes, where BACE1/β-S and γ-S cleavages take place [85].
Thence, Aβ is retrotransported to late endosomes/multivesicular bod-
ies (MVBs) [86]. When Aβ production is raised, a small fraction (1%)
of Aβ42 accumulates in ﬂotillin-1-positive endosomes/MVBs. Follow-
ing MVBs fusion with the plasma membrane, the inner vesicles of
MVBs and their associated Aβ42 moieties are released extracellularly
as exosomes [86,87]. But a pool of Aβ42 is released not bound to
the exosomes [88]. Our results suggest that by antagonising Aβ/
CaSR signalling NPS 2143 might hinder the subcellular TGN- and
endosome-related intracellular transport and distribution of endoge-
nous Aβ42 bound to endosomal vesicles/MVBs, which are essential for
an excess secretion of the Aβ42 peptides. Evidence from Busciglio et
al. [19] indicated that Golgi processing is needed for the secretion of
Aβs. Further studies will clarify in their ﬁne molecular details how
calcilytic compounds speciﬁcally hinder the processes underlying en-
dogenous Aβ42 over-secretion by exogenous Aβ-exposed human
neurons.
4.4. AD progression via exogenous Aβ-induced endogenous Aβ42 release
by neurons and astrocytes
So, what might be the import of our present observations on AD
onset and progression? Do they signal novel therapeutic approaches
to this unforgiving ailment? If these observations made in cultured
human adult astrocytes and postnatal neurons reﬂect in vivo brain
reality, they raise the possibility of the operation of a signiﬁcant
astrocyte-assisted Aβ-induced increase in the Aβs load of the AD
brain. Extracellular Aβ was previously reported to upregulate intracel-
lular Aβ in APP overexpressing cells [89]. And cultured foetal human
neurons and astrocytes have the ability to produce/secrete surplus Aβ
peptides [90]. It is virtually certain that the Aβs released by neuronsonce locally accumulated over a basal threshold due to failing removal
mechanisms [4] would impact on their cradling astrocytes. Initial reac-
tions of astrocytes to Aβs accumulation in triple transgenic mice
(3xTg-AD) harboring mutated APPSwe, 1PS1M146V and tauP301L would
consist in cell degeneration/atrophy thereby contributing to synaptic
loss [91,92]. Later on, rodent astrocytes become activated, phagocyte
and degrade accumulated Aβs, and start expressing BACE1/β-S thereby
becomingpossible Aβ producers [93]. Itmust be recalled here that adult
human astrocytes do have unique features with respect to their rodent
counterparts, being not only the most represented brain cell type [16]
but even having ~10-fold more primary processes and covering from
16-fold to 100-fold more synapses (see for references [92–94]). As
shown by our ﬁndings, the contact with fAβ25–35 does not induce
adult human astrocytes to degenerate, though it kills a fraction of the
HCN-1A neurons. The cultured human astrocytes basally express
BACE1/β-S, and intensify this expression after exposure to fAβ25–35
[23]. It would be expected from the present relatively fast responses
of the human astrocytes and HCN-1A neurons to externally added
f- or sAβ25–35 that the endogenous Aβ42 peptides increasingly re-
leased from the neurons in AD brains could directly stimulate the as-
trocytes they tightly associate with to make, accumulate, and secrete
mounting amounts of Aβ42 peptides [10]. Once secreted such pep-
tides would directly impact onto the spines and synapses of the
astrocyte-cradled neurons [6] and by diffusion induce neighboring
neurons and astrocytes to produce and release further amounts of
Aβs. This might start a self-sustained spreading of oligomeric Aβ42
peptides through astrocytes⇔ neurons, neurons⇔ neurons, and
astrocytes⇔ astrocytes along established trajectories in the
AD-developing brains [94–97]. Thus, the present results together with
the toxic spread of oligomeric Aβ42 peptides from neuron-to-neuron
demonstrated by Nath et al. [94] suggest that a self-sustaining and
self-amplifying Aβs spread would initially drive the decades-long, but
gradually accelerating, diffusion of synapse-disconnecting oligomeric
Aβs through neocortical networks and the reciprocally interlinked en-
torhinal cortex and hippocampi [94–98]. Indeed, such a feed-forward
mechanism of Aβ self-induction and excess release by the astrocytes
and neurons might have helped spread the β-amyloidosis throughout
the brains of young APP23 AD-transgenic mice andmarmoset monkeys
[99–101] during four months after injection into their hippocampi and
overlying neocortices of stainless steel wires coated with a dried
Aβ-containing brain extract from aged APP23 mice. Moreover, the sur-
plus Aβ42 released by both astrocytes and neurons would activate mi-
croglia, which would in turn secrete proinﬂammatory cytokines
capable of further enhancing the production and release of Aβ42 and
Aβ40, besides VEGF-A isoforms and NO by the astrocytes, thereby
reinforcing a vicious cycle [20,21,37,38,53,60]. Therefore, LOAD may
arise from both an age-related failure of the Aβ-clearing brain
mechanisms and the locally accumulating exogenous Aβ-induced
overproduction, accrual, secretion, and spreading of endogenous
Aβ oligomers by both neurons and astrocytes reinforced by
neuroinﬂammatory mechanisms mediated by activated astrocytes and
microglia.
4.5. Conclusions and potential therapeutic impact on AD
The present results clearly indicate that Aβs accumulating in the
extracellular spaces can stimulate via CaSR signalling both human
neurons and astrocytes to make and secrete much higher amounts
of endogenous Aβ42 peptides, besides other compounds, like the
VEGF-A isoforms and NO, released by astrocytes ([37,53] and present
results). The upshots of these activities would be (i) the loss of
synapses, (ii) the killing of neurons and, maybe, of their associated as-
trocytes, and (iii) the local diffusion of newly produced and secreted
Aβs driving adjacent neurons and astrocytes to produce and release
further surplus amounts of endogenous Aβ42. By this means, the cy-
cles of “Aβ self-induction” and consequent Aβ excess production
1650 U. Armato et al. / Biochimica et Biophysica Acta 1832 (2013) 1634–1652and release would keep going on slowly, nearly at a subliminal level,
until a lethal endpoint is reached. This self-sustained spreading of Aβs
and its neuropathological and cognitive consequences would explain
the inexorable though relatively slow progression of AD. The present
ﬁndings indicate that CaSR allosteric antagonists would halt the de-
velopment of this process and hence the progression to full AD by
speciﬁcally and effectively preventing any excess (but not basal) en-
dogenous Aβ42 release by both neurons and astrocytes. We are well
aware that extrapolating our present results to in vivo settings re-
quires wariness and self-restraint. However, our ﬁndings were gained
from untransformed human cerebral cortical adult astrocytes and
postnatal neurons. A similar self-inducing activity of exogenous Aβs
has been observed in cultured rat embryo/neonatal neurons [24]. Al-
together, these ﬁndings strengthen the idea that the production of
endogenous Aβs can be induced by the exposure to locally increased
levels of Aβs in both neurons and astrocytes if not in other nerve cell
types too. Hence, we may envision that a proper therapeutic use of
NPS 2143 or other calcilytic compound, besides anabolically improv-
ing age-related osteoporosis [36,48], would prevent the Aβ-elicited
overproduction and over-secretion of Aβs and hence obstruct the
otherwise inexorable path to full blown AD, thereby preserving
nerve cells viability and functions and with them the patients' higher
cognitive functions. These preliminary results have enticed us to plan
further studies with transgenic AD-model mice to be treated with
NPS 2143 to assess both biochemical and behavioral end points that
would determine the full value of NPS 2143 as a beneﬁcial AD thera-
peutic drug.
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